0001517681 false Q1 --06-30 2023 1 1 1 1 P0Y P3Y P3Y P1Y P1Y 0001517681 2022-07-01 2022-09-30 0001517681 2022-11-11 0001517681 2022-09-30 0001517681 2022-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001517681 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001517681 us-gaap:SeriesBPreferredStockMember 2022-06-30 0001517681 2021-07-01 2021-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-06-30 0001517681 us-gaap:CommonStockMember 2021-06-30 0001517681 PPCB:CommonStockIssuableMember 2021-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001517681 PPCB:SubscriptionReceivableMember 2021-06-30 0001517681 us-gaap:RetainedEarningsMember 2021-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001517681 us-gaap:TreasuryStockMember 2021-06-30 0001517681 2021-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-06-30 0001517681 us-gaap:CommonStockMember 2022-06-30 0001517681 PPCB:CommonStockIssuableMember 2022-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001517681 PPCB:SubscriptionReceivableMember 2022-06-30 0001517681 us-gaap:RetainedEarningsMember 2022-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001517681 us-gaap:TreasuryStockMember 2022-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0001517681 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001517681 PPCB:CommonStockIssuableMember 2021-07-01 2021-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001517681 PPCB:SubscriptionReceivableMember 2021-07-01 2021-09-30 0001517681 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001517681 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-07-01 2022-09-30 0001517681 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001517681 PPCB:CommonStockIssuableMember 2022-07-01 2022-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001517681 PPCB:SubscriptionReceivableMember 2022-07-01 2022-09-30 0001517681 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001517681 us-gaap:TreasuryStockMember 2022-07-01 2022-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001517681 us-gaap:CommonStockMember 2021-09-30 0001517681 PPCB:CommonStockIssuableMember 2021-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001517681 PPCB:SubscriptionReceivableMember 2021-09-30 0001517681 us-gaap:RetainedEarningsMember 2021-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001517681 us-gaap:TreasuryStockMember 2021-09-30 0001517681 2021-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-09-30 0001517681 us-gaap:CommonStockMember 2022-09-30 0001517681 PPCB:CommonStockIssuableMember 2022-09-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001517681 PPCB:SubscriptionReceivableMember 2022-09-30 0001517681 us-gaap:RetainedEarningsMember 2022-09-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001517681 us-gaap:TreasuryStockMember 2022-09-30 0001517681 us-gaap:CommonStockMember 2022-05-18 0001517681 us-gaap:CommonStockMember srt:MinimumMember 2022-05-18 0001517681 us-gaap:CommonStockMember srt:MaximumMember 2022-05-18 0001517681 us-gaap:PreferredStockMember srt:MaximumMember 2022-05-18 0001517681 2022-05-16 2022-05-18 0001517681 us-gaap:CommonStockMember 2022-09-21 0001517681 us-gaap:CommonStockMember srt:MinimumMember 2022-09-21 0001517681 us-gaap:CommonStockMember srt:MaximumMember 2022-09-21 0001517681 us-gaap:PreferredStockMember srt:MaximumMember 2022-09-21 0001517681 2022-09-21 2022-09-21 0001517681 PPCB:IntercompanyLoansMember 2022-07-01 2022-09-30 0001517681 PPCB:IntercompanyLoansMember 2021-07-01 2021-09-30 0001517681 srt:WeightedAverageMember 2022-09-30 0001517681 srt:WeightedAverageMember 2022-06-30 0001517681 us-gaap:MachineryAndEquipmentMember 2022-07-01 2022-09-30 0001517681 us-gaap:FurnitureAndFixturesMember 2022-07-01 2022-09-30 0001517681 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001517681 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001517681 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001517681 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001517681 PPCB:SeriesAWarrantsMember 2022-07-01 2022-09-30 0001517681 PPCB:SeriesAWarrantsMember 2021-07-01 2021-09-30 0001517681 PPCB:SeriesBWarrantsMember 2022-07-01 2022-09-30 0001517681 PPCB:SeriesBWarrantsMember 2021-07-01 2021-09-30 0001517681 PPCB:SeriesCWarrantsMember 2022-07-01 2022-09-30 0001517681 PPCB:SeriesCWarrantsMember 2021-07-01 2021-09-30 0001517681 PPCB:UnvestedRestrictedStockMember 2022-07-01 2022-09-30 0001517681 PPCB:UnvestedRestrictedStockMember 2021-07-01 2021-09-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0001517681 PPCB:DirectorsAndOfficerMember 2022-09-30 0001517681 PPCB:DirectorsAndOfficerMember 2022-06-30 0001517681 2017-08-10 0001517681 2017-08-09 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-08-09 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2018-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-08-07 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:ConsultantMember 2018-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:ConsultantMember 2019-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2019-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2020-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2021-03-15 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2022-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2021-07-01 2022-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2022-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2022-09-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2022-07-01 2022-09-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember srt:MinimumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember srt:MaximumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-09-15 2020-09-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OctoberTwentyOneTwoThousandTwentyOneMember PPCB:OneThousandEightHundredDiagonalLendingMember 2021-10-21 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OctoberTwentyOneTwoThousandTwentyOneMember PPCB:OneThousandEightHundredDiagonalLendingMember 2021-10-20 2021-10-21 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:NovemberTwentySixTwoThousandTwentyOneMember PPCB:OneThousandEightHundredDiagonalLendingMember 2021-11-26 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:NovemberTwentySixTwoThousandTwentyOneMember PPCB:OneThousandEightHundredDiagonalLendingMember 2021-11-25 2021-11-26 0001517681 PPCB:JanuaryFourTwoThousandTwentyTwoMember PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-01-04 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryFourTwoThousandTwentyTwoMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-01-01 2022-01-04 0001517681 PPCB:MarchSevenTwoThousandTwentyTwoMember PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-03-07 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchSevenTwoThousandTwentyTwoMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-03-06 2022-03-07 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:AprilTwelveTwoThousandAndTwentyTwoMember 2022-04-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:AprilTwelveTwoThousandAndTwentyTwoMember 2022-04-10 2022-04-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:MayTwelveTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-05-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:MayTwelveTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-05-10 2022-05-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-06-01 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember srt:MinimumMember 2022-06-01 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember srt:MaximumMember 2022-06-01 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-07-01 2022-09-30 0001517681 PPCB:SixthStreetFinancingAgreementMember PPCB:MayTwelveTwentyTwentyTwoThousandEighthundredDiagonalNoteMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-06-30 0001517681 PPCB:SixthStreetFinancingAgreementMember PPCB:MayTwelveTwentyTwentyTwoThousandEighthundredDiagonalNoteMember PPCB:OneThousandEightHundredDiagonalLendingMember 2021-07-01 2022-06-30 0001517681 PPCB:MayTwelveTwentyTwentyTwoThousandEighthundredDiagonalNoteMember PPCB:OneThousandEightHundredDiagonalLendingMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-09-30 0001517681 PPCB:OneThousandEightHundredDiagonalLendingMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberSevenTwoThousandTwentyOneGenevaRothMember PPCB:OneFortyFourCapitalMember 2021-12-07 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberSevenTwoThousandTwentyOneGenevaRothMember PPCB:OneFortyFourCapitalMember 2021-12-06 2021-12-07 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchTwentyNineTwoThousandTwentyTwoMember PPCB:OneFortyFourCapitalMember 2022-03-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchTwentyNineTwoThousandTwentyTwoMember PPCB:OneFortyFourCapitalMember 2022-03-21 2022-03-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-14 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MinimumMember 2022-08-14 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MaximumMember 2022-08-14 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchTwentyNineTwoThousandTwentyTwoMember PPCB:OneFortyFourCapitalMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchTwentyNineTwoThousandTwentyTwoMember PPCB:OneFortyFourCapitalMember 2021-07-01 2022-06-30 0001517681 PPCB:MarchTwentyNineTwoThousandTwentyTwoMember PPCB:OneFortyFourCapitalMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-07-01 2022-09-30 0001517681 PPCB:OneFortyFourCapitalMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-08-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-08-11 2022-08-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-09-21 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-09-20 2022-09-21 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember srt:MinimumMember 2022-09-20 2022-09-21 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember srt:MaximumMember 2022-09-20 2022-09-21 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2022-09-30 0001517681 PPCB:OneConvertibleNotesMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2022-07-01 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2021-07-01 2021-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2022-09-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2021-09-30 0001517681 2022-05-18 0001517681 2022-05-17 0001517681 2022-09-21 0001517681 2022-09-20 0001517681 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001517681 us-gaap:SeriesBPreferredStockMember PPCB:NathanielszMember 2022-09-30 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember srt:MaximumMember 2021-11-28 2021-11-30 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember 2021-11-28 2021-11-30 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember 2021-11-30 0001517681 us-gaap:CommonStockMember 2022-07-12 2022-07-13 0001517681 us-gaap:CommonStockMember 2022-07-13 0001517681 2022-07-12 2022-07-13 0001517681 us-gaap:ConvertibleDebtMember 2022-06-30 0001517681 us-gaap:ConvertibleDebtMember 2022-07-12 0001517681 us-gaap:ConvertibleDebtMember 2021-07-01 2022-09-14 0001517681 us-gaap:ConvertibleDebtMember 2022-09-30 0001517681 us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-14 0001517681 PPCB:UnderlyingFinancingAgreementsMember 2022-09-30 0001517681 2022-06-01 2022-06-30 0001517681 2022-06-29 2022-07-02 0001517681 2022-09-09 2022-09-09 0001517681 PPCB:SeriesBWarrantsMember 2022-09-09 2022-09-09 0001517681 us-gaap:CommonStockMember 2022-07-29 2022-07-29 0001517681 us-gaap:CommonStockMember 2022-09-09 2022-09-09 0001517681 us-gaap:SubsequentEventMember PPCB:SeriesBWarrantsMember 2022-10-01 2022-10-31 0001517681 PPCB:SeriesAAndCWarrantMember 2022-07-01 2022-09-30 0001517681 PPCB:SeriesAWarrantsMember 2022-09-30 0001517681 PPCB:SeriesAWarrantMember 2022-09-30 0001517681 PPCB:SeriesAWarrantsMember 2022-07-01 2022-09-30 0001517681 srt:ChiefExecutiveOfficerMember 2019-05-01 2019-05-31 0001517681 PPCB:ChiefScientificOfficerMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001517681 PPCB:UnvestedRestrictedStockUnitsMember 2022-09-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001517681 us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:WarrantMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-09-01 2022-09-30 0001517681 PPCB:TwoThousandNinteenEquityIncentivePlanMember 2022-09-30 0001517681 PPCB:SeriesAWarrantsMember 2022-09-30 0001517681 PPCB:SeriesBWarrantsMember 2022-09-30 0001517681 PPCB:SeriesCWarrantsMember 2022-09-30 0001517681 PPCB:WarrantsWithNoClassDesignationMember 2022-09-30 0001517681 PPCB:From2012ThroughThe2014Member 2022-07-01 2022-09-30 0001517681 us-gaap:RoyaltyAgreementTermsMember 2012-06-01 2012-06-30 0001517681 us-gaap:LicenseAgreementTermsMember 2012-06-01 2012-06-30 0001517681 PPCB:OneYearCollaborationAgreementMember 2018-09-10 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2018-09-10 2018-09-13 0001517681 2018-07-01 2019-06-30 0001517681 2020-07-01 2021-06-30 0001517681 PPCB:TwoYearCollaborationAgreementMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentOneMember 2020-11-01 2020-11-30 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentTwoMember 2021-03-01 2021-03-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentThreeMember 2021-12-01 2021-12-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentFourMember 2022-09-01 2022-09-30 0001517681 PPCB:UniversityOfJaenMember 2020-09-29 2020-10-02 0001517681 2020-09-29 2020-10-02 0001517681 us-gaap:SalesRevenueNetMember PPCB:UniversityOfJaenMember us-gaap:RevenueFromRightsConcentrationRiskMember PPCB:NoCustomerMember PPCB:ResearchAgreementMember 2022-07-26 2022-07-27 0001517681 PPCB:ResearchAgreementMember 2022-07-26 2022-07-27 0001517681 PPCB:InstallmentOneMember PPCB:ResearchAgreementMember 2022-07-26 2022-07-27 0001517681 PPCB:InstallmentTwoMember PPCB:ResearchAgreementMember 2022-09-01 2022-09-30 0001517681 PPCB:InstallmentThreeMember PPCB:ResearchAgreementMember 2022-12-01 2022-12-31 0001517681 srt:ScenarioForecastMember PPCB:InstallmentFourMember PPCB:ResearchAgreementMember 2023-03-01 2023-03-31 0001517681 srt:ScenarioForecastMember PPCB:InstallmentFiveMember PPCB:ResearchAgreementMember 2023-07-01 2023-07-31 0001517681 PPCB:ConsultingAgreementMember 2022-06-29 2022-07-02 0001517681 PPCB:ConsultingAgreementMember 2022-07-02 0001517681 PPCB:ConsultingAgreementMember 2022-09-30 0001517681 PPCB:NewFiveYearOperatingLeaseAgreementMember 2022-05-04 0001517681 PPCB:NewFiveYearOperatingLeaseAgreementMember 2022-05-04 2022-05-04 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2022-05-04 0001517681 PPCB:FormerDirectorMember 2022-09-30 0001517681 PPCB:FormerDirectorMember 2022-06-30 0001517681 PPCB:NorthHorizonPtyLtdMember 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember 2022-05-04 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:NathanielszMember 2022-09-30 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:NathanielszMember 2022-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2015-02-24 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember 2022-07-01 2022-09-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2021-07-01 2022-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2015-02-24 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2018-03-15 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2018-03-15 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2022-07-28 2022-08-02 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2022-07-28 2022-08-02 0001517681 PPCB:MrsNathanielszMember 2018-01-28 2018-02-01 0001517681 PPCB:JamesNathanielszMember 2016-02-24 2016-02-25 0001517681 PPCB:MrsNathanielszMember 2021-07-01 2022-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2019-05-13 2019-05-14 0001517681 srt:ChiefExecutiveOfficerMember 2018-07-01 2019-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2020-07-12 2020-07-13 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember PPCB:AUDCurrenryMember 2020-07-12 2020-07-13 0001517681 srt:ChiefExecutiveOfficerMember 2019-07-01 2020-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2021-08-11 2021-08-12 0001517681 srt:ChiefExecutiveOfficerMember 2020-07-01 2021-06-30 0001517681 srt:ChiefExecutiveOfficerMember PPCB:MrsNathanielszMember 2020-07-01 2021-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2022-07-29 2022-08-02 0001517681 2021-07-01 2022-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-09-30 0001517681 PPCB:EmploymentAgreementMember PPCB:MrNathanielszMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:InitialNathanielszRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:AdditionalNathanielszRSUsMember 2022-07-01 2022-09-30 0001517681 PPCB:EmploymentAgreementMember PPCB:AdditionaNathanielszRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember 2019-05-13 2019-05-14 0001517681 PPCB:NathanielszEmploymentAgreementMember us-gaap:SubsequentEventMember 2022-10-25 2022-10-26 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2022-07-01 2022-09-30 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMemberMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:InitialKenyonRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:AdditionalKenyonRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:CancellationAgreementMember PPCB:DrKenyonMember 2021-08-12 0001517681 PPCB:CancellationAgreementMember PPCB:DrKenyonMember 2021-08-11 2021-08-12 0001517681 PPCB:LenderOneMember 2022-07-01 2022-09-30 0001517681 PPCB:LenderTwoMember 2022-07-01 2022-09-30 0001517681 PPCB:LenderThreeMember 2022-07-01 2022-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderOneMember 2022-07-01 2022-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderTwoMember 2022-07-01 2022-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderThreeMember 2022-07-01 2022-09-30 0001517681 PPCB:LenderMember 2021-07-01 2021-09-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember 2021-07-01 2021-09-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2022-07-01 2022-09-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2021-07-01 2022-06-30 0001517681 us-gaap:ConvertibleDebtMember 2022-09-30 0001517681 us-gaap:ConvertibleDebtMember 2022-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember srt:MinimumMember PPCB:NewDerivativeInstrumentsMember 2022-09-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember srt:MaximumMember PPCB:NewDerivativeInstrumentsMember 2022-09-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember PPCB:NewDerivativeInstrumentsMember 2022-07-01 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember PPCB:NewDerivativeInstrumentsMember 2022-07-01 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2022-07-01 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2022-07-01 2022-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MinimumMember PPCB:NewDerivativeInstrumentsMember 2022-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MaximumMember PPCB:NewDerivativeInstrumentsMember 2022-09-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember 2022-09-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ConvertibleDebtMember 2022-09-30 0001517681 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001517681 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001517681 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001517681 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001517681 us-gaap:SubsequentEventMember 2022-10-01 2022-11-30 0001517681 us-gaap:SubsequentEventMember 2022-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-10-06 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-10-06 2022-10-06 0001517681 PPCB:SeriesAWarrantMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001517681 us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001517681 PPCB:SeriesBWarrantMember us-gaap:SubsequentEventMember 2021-10-01 2022-10-31 0001517681 PPCB:SeriesBWarrantMember us-gaap:SubsequentEventMember 2022-10-31 0001517681 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-31 0001517681 us-gaap:SubsequentEventMember us-gaap:CommonStockMember PPCB:ConsultantMember 2021-10-01 2022-10-31 0001517681 PPCB:AmendedAndRestatedEmploymentAgreementMember us-gaap:SubsequentEventMember 2022-10-26 0001517681 PPCB:AmendedAndRestatedEmploymentAgreementMember us-gaap:SubsequentEventMember srt:MaximumMember 2022-10-26 2022-10-26 0001517681 PPCB:AmendedAndRestatedEmploymentAgreementMember us-gaap:SubsequentEventMember 2022-10-26 2022-10-26 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember srt:MaximumMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember 2022-11-03 2022-11-03 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember us-gaap:SubsequentEventMember 2022-11-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-11-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 0001517681 PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PPCB:Integer iso4217:EUR iso4217:AUD xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission File Number: 000-54878

 

PROPANC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   33-0662986

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

302, 6 Butler Street

Camberwell, VIC, 3124 Australia

(Address of principal executive offices) (Zip Code)

 

+61-03- 9882-0780

(Registrant’s telephone number, including area code)

 

n/a

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 11, 2022, there were 889,745,790 shares of the registrant’s common stock, $0.001 par value per share, issued and outstanding.

 

 

 

 

 

 

PROPANC BIOPHARMA INC.

 

Table of Contents

 

    Page
PART I - FINANCIAL INFORMATION  
     
Item 1. Financial Statements F-1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3. Quantitative and Qualitative Disclosures About Market Risk 7
Item 4. Controls and Procedures 7
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 8
Item 1A. Risk Factors 8
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
Item 3. Defaults Upon Senior Securities 9
Item 4. Mine Safety Disclosures 9
Item 5. Other Information 9
Item 6. Exhibits 9
  Signatures 10

 

2

 

 

PART I — FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Report on Form 10-Q:

 

INDEX TO FINANCIAL STATEMENTS

 

  Page
Condensed Consolidated Balance Sheets at September 30, 2022 (unaudited) and June 30, 2022 F-2
   
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended September 30, 2022 and 2021 (unaudited) F-3
   
Condensed Consolidated Statements of Changes in Stockholders’ Deficit for each of the three months in the periods ended September 30, 2022 and 2021 (unaudited) F-4
   
Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2022 and 2021 (unaudited) F-5
   
Notes to the Condensed Consolidated Financial Statements (unaudited) F-6

 

F-1

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

 

           
   September 30, 2022   June 30, 2022 
   (Unaudited)     
ASSETS          
           
CURRENT ASSETS:          
Cash  $19,396   $4,067 
GST tax receivable   2,701    2,342 
Prepaid expenses and other current assets   15,765    8,621 
           
TOTAL CURRENT ASSETS   37,862    15,030 
           
Security deposit - related party   1,930    2,075 
Operating lease right-of-use assets, net - related party   53,025    62,523 
Property and equipment, net   1,437    2,023 
           
TOTAL ASSETS  $94,254   $81,651 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable  $899,225   $943,023 
Accrued expenses and other payables   448,719    466,115 
Convertible notes and related accrued interest, net of discounts and premiums   913,641    984,260 
Operating lease liability - related party, current portion   14,516    20,605 
Embedded conversion option liabilities   72,958    151,262 
Due to former director - related party   28,599    30,746 
Loan from former director - related party   47,597    51,171 
Employee benefit liability   397,171    415,799 
           
TOTAL CURRENT LIABILITIES   2,822,426    3,062,981 
           
NON-CURRENT LIABILITIES:          
Operating lease liability - long-term portion - related party   39,363    42,319 
           
TOTAL NON-CURRENT LIABILITIES   39,363    42,319 
           
TOTAL LIABILITIES  $2,861,789   $3,105,300 
           
Commitments and Contingencies (See Note 8)   -      
           
STOCKHOLDERS’ DEFICIT:          
Preferred stock, 1,500,005 shares authorized, $0.01 par value:          
Series A preferred stock, $0.01 par value; 500,000 shares authorized; 500,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022  $5,000   $5,000 
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of September 30, 2022 and June 30, 2022   -    - 
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 677,177,717 and 220,350,921 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively   677,178    220,351 
Common stock issuable (1,309 and 19,597,024 shares as of September 30, 2022 and June 30, 2022, respectively)   1    19,597 
Additional paid-in capital   57,800,241    57,124,982 
Subscription receivable   -    (23,758)
Accumulated other comprehensive income   1,360,945    1,234,549 
Accumulated deficit   (62,564,423)   (61,557,893)
Treasury stock (1 share)   (46,477)   (46,477)
           
TOTAL STOCKHOLDERS’ DEFICIT   (2,767,535)   (3,023,649)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $94,254   $81,651 

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

           
   For the three months ended September 30, 
   2022   2021 
         
REVENUE          
Revenue  $-   $- 
           
OPERATING EXPENSES          
Administration expenses   465,132    431,740 
Occupancy expenses - related party   6,373    7,736 
Research and development   101,325    46,554 
TOTAL OPERATING EXPENSES   572,830    486,030 
           
LOSS FROM OPERATIONS   (572,830)   (486,030)
           
OTHER INCOME (EXPENSE)          
Interest expense   (162,752)   (109,853)
Interest income   2    - 
Change in fair value of derivative liabilities   65,173    (3,904)
Gain from settlement of accounts payable   17,499    - 
Loss on extinguishment of debt, net   (610)   - 
Foreign currency transaction gain   36,223    109,129 
TOTAL OTHER EXPENSE, NET   (44,465)   (4,628)
           
LOSS BEFORE TAXES   (617,295)   (490,658)
           
Tax benefit   -    - 
           
NET LOSS  $(617,295)  $(490,658)
           
Deemed Dividend   (389,235)   (114,844)
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(1,006,530)  $(605,502)
           
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS  $(0.00)  $(0.02)
           
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING   473,589,083    27,142,519 
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(1,006,530)  $(605,502)
           
OTHER COMPREHENSIVE INCOME          
Unrealized foreign currency translation gain   126,396    64,193 
           
TOTAL OTHER COMPREHENSIVE INCOME   126,396    64,193 
           
TOTAL COMPREHENSIVE LOSS  $(880,134)  $(541,309)

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE THREE
MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

(Unaudited)

 

                                                                       
                                        
   Preferred Stock           Common Stock               Accumulated        
   Series A   Series B   Common Stock   Issuable   Additional          Other       Total 
   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   Paid-in Capital   Subscription Receivable  

Accumulated

  Deficit

   Comprehensive Income   Treasury Stock   Stockholders’ Deficit 
                                                         
Balance at June 30, 2021   500,000   $5,000    1   $-    14,055,393   $14,056    59   $-   $54,074,110   $-   $(58,199,466)  $1,085,204   $(46,477)  $     (3,067,573)
                                                                       
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest   -    -    -    -    9,445,009    9,445    -    -    190,741    -    -    -    -    200,186 
                                                                       
Issuance of common stock for services and accrued expenses   -    -    -    -    17,934,379    17,934    -    -    563,927    -    -    -    -    581,861 
                                                                       
Issuance of common stock for exercise of warrants   -    -    -    -    6,875    7    2,500    2    374,991    (100,000)   -    -    -    275,000 
                                                                       
Issuance of common stock for alternate cashless exercise of warrants   -    -    -    -    2,399,988    2,400    1,999,990    2,000    (4,400)   -    -    -    -    - 
                                                                       
Reclassification of put premium upon debt conversion   -    -    -    -    -    -    -    -    109,643    -    -    -    -    109,643 
                                                                       
Stock based compensation in connection with stock option grants   -    -    -    -    -    -    -    -    20,718    -    -    -    -    20,718 
                                                                       
Foreign currency translation gain   -    -    -    -    -    -    -    -    -    -    -    64,193    -    64,193 
                                                                       
Deemed dividend upon alternate cashless exercise of warrants   -    -    -    -    -    -    -    -    114,844    -    (114,844)   -    -    - 
                                                                       
Net loss for the three months ended September 30, 2021   -    -    -    -    -    -    -    -    -    -    (490,658)   -    -    (490,658)
                                                                       
Balance at September 30, 2021   500,000   $5,000    1   $-    43,841,644   $43,842    2,002,549   $2,002   $55,444,574   $(100,000)  $(58,804,968)  $1,149,397   $(46,477)  $(2,306,630)

 

                                        
   Preferred Stock           Common Stock               Accumulated        
   Series A   Series B   Common Stock   Issuable   Additional         Other      Total 
   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   Paid-in Capital   Subscription Receivable   Accumulated Deficit   Comprehensive Income   Treasury Stock   Stockholders’ Deficit 
                                                         
Balance at June 30, 2022   500,000   $5,000    1   $-    220,350,921   $220,351    19,597,024   $19,597   $57,124,982   $(23,758)  $(61,557,893)  $1,234,549   $(46,477)  $      (3,023,649)
                                                                       
Issuance of common stock for cash   -    -    -    -    14,336,712    14,337    -    -    10,374    23,758    -    -    -    48,469 
                                                                       
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest   -    -    -    -    264,492,661    264,493    -    -    192,446    -    -    -    -    456,939 
                                                                       
Issuance of common stock for issuable shares   -    -    -    -    19,596,965    19,597    (19,596,965)   (19,597)   -    -    -    -    -    - 
                                                                       
Issuance of common stock for exercise of warrants   -    -    -    -    1,250    1    1,250    1    99,998    -    -    -    -    100,000 
                                                                       
Issuance of common stock for alternate cashless exercise of warrants   -    -    -    -    158,399,208    158,399    -    -    (158,399)   -    -    -    -    - 
                                                                       
Reclassification of put premium upon debt conversion   -    -    -    -    -    -    -    -    133,646    -    -    -    -    133,646 
                                                                       
Stock based compensation in connection with stock warrant grant   -    -    -    -    -    -    -    -    2,408    -    -    -    -    2,408 
                                                                       
Stock warrant grant for settlement of accounts payable   -    -    -    -    -    -    -    -    5,551    -    -    -    -    5,551 
                                                                       
Foreign currency translation gain   -    -    -    -    -    -    -    -    -    -    -    126,396    -    126,396 
                                                                       
Deemed dividend upon alternate cashless exercise of warrants   -    -    -    -    -    -    -    -    389,235    -    (389,235)   -    -    - 
                                                                       
Net loss for the three months ended September 30, 2022   -    -    -    -    -    -    -    -    -    -    (617,295)   -    -    (617,295)
                                                                       
Balance at September 30, 2022   500,000   $5,000    1   $-    677,177,717   $677,178    1,309   $1   $57,800,241   $-   $(62,564,423)  $1,360,945   $(46,477)  $(2,767,535)

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

           
   For the three months ended
September 30,
 
   2022    2021 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(617,295)  $(490,658)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:          
Issuance and amortization of common stock for services   -    133,422 
Foreign currency transaction gain   (36,223)   (109,129)
Depreciation expense   473    509 
Amortization of debt discounts   31,275    6,074 
Amortization of right-of-use assets   5,131    - 
Change in fair value of derivative liabilities   (65,173)   3,904 
Loss on extinguishment of debt, net   610    - 
Gain from settlement of accounts payable   (17,499)   - 
Stock option, stock warrants and restricted stock expense   2,408    20,718 
Non-cash interest expense   -    2,250 
Accretion of put premium   115,769    90,192 
Changes in Assets and Liabilities:          
GST receivable   (523)   1,937 
Prepaid expenses and other assets   (7,747)   (8,353)
Accounts payable   45,121    (137,927)
Employee benefit liability   10,415    4,067 
Accrued expenses and other payables   15,162    (15,102)
Accrued interest   13,430    11,338 
Operating lease liability   (4,649)   - 
NET CASH USED IN OPERATING ACTIVITIES   (509,315)   (486,758)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from convertible promissory notes, net of original issue discounts and issue costs   345,750    160,000 
Proceeds from the sale of common stock   24,711    - 
Collection of subscription receivable   23,758    - 
Proceeds from the exercise of warrants   100,000    275,000 
NET CASH PROVIDED BY FINANCING ACTIVITIES   494,219    435,000 
           
Effect of exchange rate changes on cash   30,425    95,320 
           
NET INCREASE IN CASH   15,329    43,562 
           
CASH AT BEGINNING OF PERIOD   4,067    2,255 
CASH AT END OF PERIOD  $19,396   $45,817 
           
Supplemental Disclosure of Cash Flow Information          
          
Cash paid during the period:          
Interest  $2,277   $- 
Income Tax  $-   $- 
           
Supplemental Disclosure of Non-Cash Investing and Financing Activities          
           
Subscription receivable  $-   $100,000 
Reduction of put premium related to conversions of convertible notes  $133,646   $109,643 
Conversion of convertible notes and accrued interest to common stock  $349,530   $197,936 
Discounts related to derivative liability  $93,668   $- 
Stock warrant grant for settlement of accounts payable  $23,050   $- 
Common stock issued for accrued services  $-   $448,440 
Warrants issued for accrued services  $

5,551

   $

-

 
Deemed dividend upon alternate cashless exercise of warrants  $389,235   $114,844 

 

The accompanying unaudited condensed notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-5

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES

 

Nature of Operations

 

Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development.

 

On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company.

 

On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2022, there has been no activity within this entity.

 

Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development.

 

In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 45 granted, allowed, or accepted patents and 20 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP.

 

The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.

 

On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 1,000,000,000 to 3,000,000,000. The number of authorized shares of preferred stock remains at 1,500,005, such that the total number of shares of all classes and series the Company is authorized to issue is 3,001,500,005 shares. The Certificate was filed and became effective on July 6, 2022.

 

On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 3,000,000,000 to 10,000,000,000. The number of authorized shares of preferred stock remains at 1,500,005, such that the total number of shares of all classes and series the Company is authorized to issue is 10,001,500,005 shares. The Certificate was filed and became effective on November 4, 2022. This increase is presented retroactively on the condensed consolidated balance sheet.

 

Basis of Presentation

 

The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2022 and 2021 and cash flows for the three months ended September 30, 2022 and 2021 and our consolidated financial position at September 30, 2022 have been made. The Company’s results of operations for the three months ended September 30, 2022 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2023.

 

Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2022. The June 30, 2022 balance sheet is derived from those statements.

 

F-6

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2022.

 

Use of Estimates

 

The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.

 

Foreign Currency Translation and Other Comprehensive Income (Loss)

 

The Company’s wholly owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date.

 

Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).

 

Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of September 30, 2022 and 2021, the Company recognized a cumulative exchange gain of approximately $1,226,000 and $619,000, respectively, on intercompany loans made by the parent to the subsidiary which have not been repaid as of September 30, 2022 which is included as component of accumulated other comprehensive income on the accompanying unaudited condensed consolidated balance sheet.

 

As of September 30, 2022 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows:

 

   September 30, 2022   June 30, 2022 
Exchange rate on balance sheet dates          
USD : AUD exchange rate   0.6432    0.6915 
           
Average exchange rate for the period          
USD : AUD exchange rate   0.6836    0.7253 

 

The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2022 was as follows:

 

   Foreign
Currency Items:
 
Balance, June 30, 2022  $1,234,549 
Unrealized foreign currency translation gain   126,396 
Ending balance, September 30, 2022  $1,360,945 

 

Fair Value of Financial Instruments and Fair Value Measurements

 

The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same.

 

The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost).

 

F-7

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

 

Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

 

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of September 30, 2022 or June 30, 2022.

 

Property and Equipment

 

Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value.

 

The estimated useful lives are as follows:

 

Machinery and equipment - 5 years
Furniture - 7 years

 

Patents

 

Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2022 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.

 

Impairment of Long-Lived Assets

 

In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

 

Employee Benefit Liability

 

Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.

 

Australian Goods and Services Tax (“GST”)

 

Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.

 

Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

 

As of September 30, 2022, and June 30, 2022, the Company was owed $2,701 and $2,342, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates.

 

F-8

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

Derivative Instruments

 

ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”), establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt, the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any discounts and records a net gain or loss on debt extinguishment. On July 1, 2019 the Company adopted ASU 2017-11 under which down-round Features in Financial Instruments will no longer cause derivative treatment. The Company applied the modified prospective method of adoption. There were no cumulative effects on adoption.

 

Convertible Notes With Variable Conversion Options

 

The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “Distinguishing Liabilities from Equity” and measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion and records the put premium as interest expense.

 

Income Taxes

 

The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “Accounting for Income Taxes,” when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

 

The Company follows ASC 740, Sections 25 through 60, “Accounting for Uncertainty in Income Taxes.” These sections provide detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods.

 

Research and Development Costs and Tax Credits

 

In accordance with ASC 730-10, “Research and Development-Overall,” research and development costs are expensed when incurred. Total research and development costs for the three months ended September 30, 2022 and 2021 were $101,325 and $46,554, respectively.

 

The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt.

 

During each of the three months ended September 30, 2022 and 2021, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $0 for both periods, which is reflected as a tax benefit in the accompanying unaudited condensed consolidated statements of operations and comprehensive income (loss).

 

Stock Based Compensation

 

The Company records stock-based compensation in accordance with ASC 718, “Stock Compensation”. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

 

The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.

 

Revenue Recognition

 

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.

 

F-9

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

Legal Expenses

 

All legal costs for litigation are charged to expense as incurred.

 

Leases

 

The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.

 

Basic and Diluted Net Loss Per Common Share

 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.

 

   September 30, 2022   September 30, 2021 
   (Unaudited)   (Unaudited) 
Stock Options   59    59 
Stock Warrants with no designations   3,305,975    111,932 
Series A Warrants as if converted at alternate cashless exercise price   

2,030,789,846

    

-

 
Series B Warrants   

26,250

    

-

 
Series C Warrants as if converted at alternate cashless exercise price*   

7,499,962,500

    

-

 
Unvested restricted stock   59    59 
Convertible Debt   884,700,197    23,293,971 
Total   10,418,784,886    23,406,021 

 

*Only convertible ratably upon exercise of Series B Warrants

 

Recent Accounting Pronouncements

 

We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on our consolidated financial statements.

 

NOTE 2 – GOING CONCERN

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September 30, 2022, the Company had no revenues, had a net loss of $617,295, and had net cash used in operations of $509,315. Additionally, As of September 30, 2022, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $2,784,564, $2,767,535, and $62,564,423, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.

 

The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

 

Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

 

F-10

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

In March 2020, the outbreak of COVID-19 (coronavirus) caused by a novel strain of the coronavirus was recognized as a pandemic by the World Health Organization, and the outbreak has become increasingly widespread in the United States, Europe and Australia, including in each of the areas in which the Company operates. The COVID-19 (coronavirus) outbreak has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter in place” and other governmental regulations, reduced business and consumer spending due to both job losses, reduced investing activity and M&A transactions, among many other effects attributable to the COVID-19 (coronavirus), and there continue to be many unknowns. While to date the Company has not been required to stop operating, management is evaluating its use of its office space, virtual meetings and the like. The Company continues to monitor the impact of the COVID-19 (coronavirus) outbreak closely. The extent to which the COVID-19 (coronavirus) outbreak will impact our operations, ability to obtain financing or future financial results is uncertain.

 

NOTE 3 – PROPERTY AND EQUIPMENT

 

Property and equipment consist of the following As of September 30, 2022 and June 30, 2022.

 

   September 30, 2022   June 30, 2022 
   (Unaudited)     
Office equipment at cost  $28,600   $28,623 
Less: Accumulated depreciation   (27,163)   (26,600)
           
Total property, plant, and equipment  $1,437   $2,023 

 

Depreciation expense for the three months ended September 30, 2022 and 2021 were $473 and $509, respectively.

 

NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY

 

Due to former director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at September 30, 2022 and June 30, 2022 were $28,599 and $30,746, respectively. The Company plans to repay the advances as its cash resources allow (see Note 9).

 

NOTE 5 – LOAN FROM FORMER DIRECTOR – RELATED PARTY

 

Loan from Former Director - Related Party

 

Loan from the Company’s former director at September 30, 2022 and June 30, 2022 was $47,597 and $51,171, respectively. The loan bears no interest and is payable on demand. The Company did not repay any amount on this loan during the three months ended September 30, 2022 and 2021, respectively (see Note 9).

 

NOTE 6 – CONVERTIBLE NOTES

 

The Company’s convertible notes outstanding at September 30, 2022 and June 30, 2022 were as follows:

 

   September 30, 2022   June 30, 2022 
   (Unaudited)     
Convertible notes and debenture  $697,280   $644,980 
Unamortized discounts   (127,811)   (31,669)
Accrued interest   48,922    57,822 
Premium, net   295,250    313,127 
Convertible notes, net  $913,641   $984,260 

 

F-11

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

Convertible Note Issued with Consulting Agreement

 

August 10, 2017 Consulting Agreement

 

On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $310,000 junior subordinated convertible note. The maturity date of the August 10, 2017 Convertible Note was August 2019 and was past due (see Note 8). The note accrued interest at a rate of 10% per annum and was convertible into common stock at the lesser of $750 or 65% of the three lowest trades in the ten trading days prior to the conversion. The note was fully earned upon signing the agreement and matured on August 10, 2019. The Company accrued $155,000 related to this expense at June 30, 2017 and recorded the remaining $155,000 related to this expense in fiscal year 2018. Upon an event of default, principal and accrued interest will become immediately due and payable under the note. Additionally, upon an event of default, at the election of the holder, the note would accrue interest at a default interest rate of 18% per annum or the highest rate of interest permitted by law. The consulting agreement had a three-month term and expired on August 16, 2017. An aggregate total of $578,212 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value. During the year ended June 30, 2018, the consultant converted $140,000 of principal and $10,764 of interest. During the year ended June 30, 2019, the consultant converted an additional $161,000 of principal and $19,418 of interest leaving a principal balance owed of $9,000 at June 30, 2019. During the year ended June 30, 2020, the consultant converted an additional $500 of principal and $5,248 of interest such that the remaining principal outstanding and accrued interest under this note as of June 30, 2020 was $8,500 and $22,168, respectively.

 

On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”) with the consultant whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note for a total of $100,000 in the form of a convertible note. All other terms of the August 10, 2017 Convertible Note remained in full force and effect. Both parties agreed that all future penalties under this note were waived unless the Company failed to authorize to distribute the requested shares upon conversion. The Company had the right to pay off the balance of any remaining amounts dues under this note in cash at any time more than 60 days after March 15, 2021. Prior to the Settlement Agreement, the Company recorded total liabilities $56,762 consisting of remaining principal amount of $8,500, accrued interest of $23,262 and accrued expenses of $25,000. Accordingly, the Company recognized loss from settlement of debt of $43,238 during fiscal year 2021.

 

The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $79,000 and $10,185, respectively, as of June 30, 2022 following conversion of $1,000 of principal and $8,000 accrued interest during the year ended June 30, 2022.

 

The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $0 as of September 30, 2022 following conversion of $79,000 of principal and $9,543 accrued interest during the three months ended September 30, 2022.

 

Crown Bridge Securities Purchase Agreements

 

Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, pursuant to which Crown Bridge purchased a convertible promissory note (the “October 3, 2019 Crown Bridge Note”) from the Company in the aggregate principal amount of $108,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Crown Bridge any time from the of issuance of the of the October 3, 2019 Crown Bridge Note. The transactions contemplated by the Crown Bridge Securities Purchase Agreement closed on October 3, 2019. Pursuant to the terms of the Crown Bridge Securities Purchase Agreement, Crown Bridge deducted $3,000 from the principal payment due under the October 3, 2019 Crown Bridge Note, at the time of closing, to be applied to its legal expenses, and there was a $5,000 original issuance discount resulting in $100,000 net proceeds to the Company. The Company used the net proceeds from the October 3, 2019 Crown Bridge Note for general working capital purposes. The maturity date of the October 3, 2019 Crown Bridge was October 3, 2020 and is currently past due. The October 3, 2019 Crown Bridge Note currently bears interest at a default interest rate of 15% per annum, which interest may be paid by the Company to Crown Bridge in shares of the Company’s common stock.

 

Additionally, Crown Bridge has the option to convert all or any amount of the principal face amount of the October 3, 2019 Crown Bridge Note at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which is an amount between 110% and 150% of an amount equal to the then outstanding principal amount of the October 3, 2019 Crown Bridge Note plus any interest accrued, for shares of the Company’s common stock at the then-applicable conversion price.

 

The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to 60% ( representing a 40% discount) of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $72,000 put premium.

 

The October 3, 2019 Crown Bridge Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 15% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions.

 

The total principal amount outstanding under the above Crown Bridge financing agreement was $65,280 and accrued interest of $7,232 as of as of June 30, 2020 following conversion of $42,720 of the principal balance during the year ended June 30, 2020. Accordingly, $28,480 of the put premium was released in respect of the October 3, 2019 Crown Bridge Note during the year ended June 30, 2020 following conversion of the principal balance.

 

There were 15,000 unissued shares which were considered issuable for accounting purposes during the 1st quarter of fiscal 2021 related to a conversion notice dated and received on September 16, 2020. In November 2020, the Company was notified by the note holder of the cancellation of this conversion notice as a result of the reverse stock split and as such the Company reversed the effects of this transaction thereby increasing the principal balance by $9,600 and put premium by $6,400 and a corresponding decrease in equity of $16,000.

 

The total principal amount outstanding under the above Crown Bridge financing agreement was $65,280 and accrued interest of $25,930 as of June 30, 2022. The total principal amount outstanding under the above Crown Bridge financing agreement was $65,280 and accrued interest of $28,398 as of September 30, 2022.

 

F-12

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements

 

October 21, 2021 Securities Purchase Agreement

 

Effective October 21, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC (“Sixth Street”), pursuant to which Sixth Street purchased a convertible promissory note (the “October 21, 2021 Sixth Street”) from the Company in the aggregate principal amount of $63,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street any time after the six-month anniversary of the October 21, 2021 Sixth Street. The October 21, 2021 Sixth Street contained debt issue costs of $3,750. The Company used the net proceeds from the October 21, 2021 Sixth Street for general working capital purposes. The maturity date of the October 21, 2021 Sixth Street Note is October 21, 2022. The October 21, 2021 Sixth Street Note bore interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of the Company’s common stock; but shall not be payable until the October 21, 2021 Sixth Street Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

November 26, 2021 Securities Purchase Agreement

 

Effective November 26, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “November 26, 2021 Sixth Street”) from the Company in the aggregate principal amount of $53,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street any time after the six-month anniversary of the November 26, 2021 Sixth Street. The November 26, 2021 Sixth Street contained debt issue costs of $3,750. The Company used the net proceeds from the November 26, 2021 Sixth Street for general working capital purposes. The maturity date of the November 26, 2021 Sixth Street Note is November 26, 2022. The November 26, 2021 Sixth Street Note bore interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of the Company’s common stock; but shall not be payable until the November 26, 2021 Sixth Street Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

January 4, 2022 Securities Purchase Agreement

 

Additionally, effective January 4, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “January 4, 2022 Sixth Street”) from the Company in the aggregate principal amount of $63,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street any time after the six-month anniversary of the January 4, 2022 Sixth Street. The January 4, 2022 Sixth Street contained debt issue costs of $3,750. The Company used the net proceeds from the January 4, 2022 Sixth Street for general working capital purposes. The maturity date of the January 4, 2022 Sixth Street Note is January 4, 2023. The January 4, 2022 Sixth Street Note bore interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of the Company’s common stock; but shall not be payable until the January 4, 2022 Sixth Street Note becomes payable, whether at the maturity date or upon acceleration or by prepayment (see conversions below).

 

March 7, 2022 Securities Purchase Agreement

 

Additionally, effective March 7, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “March 7, 2022 Sixth Street”) from the Company in the aggregate principal amount of $68,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street any time after the six-month anniversary of the March 7, 2022 Sixth Street. The March 7, 2022 Sixth Street contained debt issue costs of $3,750. The Company used the net proceeds from the March 7, 2022 Sixth Street for general working capital purposes. The maturity date of the March 7, 2022 Sixth Street Note is March 7, 2023. The March 7, 2022 Sixth Street Note bore interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of the Company’s common stock; but shall not be payable until the March 7, 2022 Sixth Street Note becomes payable, whether at the maturity date or upon acceleration or by prepayment (see conversions below).

 

April 12, 2022 Securities Purchase Agreement

 

Effective April 12, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC, pursuant to which Sixth Street purchased a convertible promissory note (the “April 12, 2022 Sixth Street”) from the Company in the aggregate principal amount of $68,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street any time after the six-month anniversary of the April 12, 2022 Sixth Street. The April 12, 2022 Sixth Street contains debt issue costs of $3,750. The Company intends to use the net proceeds from the April 12, 2022 Sixth Street for general working capital purposes. The maturity date of the April 12, 2022 Sixth Street Note is April 12, 2023. The April 12, 2022 Sixth Street Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of the Company’s common stock; but shall not be payable until the April 12, 2022 Sixth Street Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

May 12, 2022 Securities Purchase Agreement

 

Effective May 12, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), pursuant to which 1800 Diagonal purchased a convertible promissory note (the “May 12, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $63,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of 1800 Diagonal any time after the six-month anniversary of the May 12, 2022 1800 Diagonal Note. The May 12, 2022 1800 Diagonal Note contains debt issue costs of $3,750. The Company intends to use the net proceeds from the May 12, 2022 1800 Diagonal Note for general working capital purposes. The maturity date of the May 12, 2022 1800 Diagonal Note is May 12, 2023. The May 12, 2022 1800 Diagonal Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to 1800 Diagonal in shares of the Company’s common stock; but shall not be payable until the May 12, 2022 1800 Diagonal Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

F-13

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

June 30, 2022 Securities Purchase Agreement

 

On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC, which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of 1800 Diagonal any time after 180 days of the July 11, 2022 1800 Diagonal Note. The July 11, 2022 1800 Diagonal Note contains debt issue cost of $3,750. The Company intends to use the net proceeds from the July 11, 2022 1800 Diagonal Note for general working capital purposes. The maturity date of the July 11, 2022 1800 Diagonal Note is June 30, 2023. The 1800 Diagonal Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to 1800 Diagonal in shares of the Company’s common stock; but shall not be payable until the July 11, 2022 1800 Diagonal Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

The following terms shall apply to all the above 1800 Diagonal notes:

 

During the first 60 to 180 days following the date of the above listed notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110% to 129% as defined in the note agreement. After this initial 180-day period, the Company does not have a right to prepay such notes.

 

The conversion price for the above 1800 Diagonal notes shall be equal to 65% (representing a 35% discount) of the market price which means the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, 1800 Diagonal shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by 1800 Diagonal and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock. All of the above 1800 Diagonal notes are treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $262,500 put premium of which $56,538 was recorded during the three months ended September 30, 2022.

 

The above 1800 Diagonal notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions.

 

Other than as described above, the above 1800 Diagonal notes contain certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Note. Additional events of default shall include, among others: (i) failure to reserve at least five times the number of shares issuable upon full conversion of the Note; (ii) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Company or any subsidiary of the Company; provided, that in the event such event is triggered without the Company’s consent, the Company shall have sixty (60) days after such event is triggered to discharge such event, (iii) the Company’s failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq Small Cap Market, the New York Stock Exchange, or the American Stock Exchange, (iv) The restatement of any financial statements filed by the Company with the SEC at any time after 180 days after the issuance date for any date or period until this note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have reasonably constituted a material adverse effect on the rights of 1800 Diagonal with respect to this note or the Purchase Agreement, and (v) the Company’s failure to comply with its reporting requirements of the Securities and Exchange Act of 1934 (the “Exchange Act”), and/or the Company ceases to be subject to the reporting requirements of the Exchange Act.

 

In the event that the Company fails to deliver the shares of common stock issuable upon conversion of principal or interest under the above 1800 Diagonal notes within three business days of a notice of conversion by 1800 Diagonal, the Company shall incur a penalty of $1,000 per day, provided, however, that such fee shall not be due if the failure to deliver the shares is a result of a third party such as the transfer agent.

 

Upon the occurrence and during the continuation of certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company will pay 1800 Diagonal in full satisfaction of its obligations in the amount equal to 150% of an amount equal to the then outstanding principal amount of the above 1800 Diagonal notes plus any interest accrued upon such event of default or prior events of default (the “Default Amount”). Further upon the occurrence and during the continuation of any event of default specified in section 3.2 as defined in the 1800 Diagonal note agreements and relates to the failure to issue shares of the Company’s common stock upon the conversion of 1800 Diagonal notes, such above 1800 Diagonal notes shall become immediately due and payable in an amount equal to the Default Amount multiplied by two.

 

The total principal amount outstanding under the above 1800 Diagonal financing agreements were $265,000 and accrued interest of $6,081 as of June 30, 2022 following conversion of $117,500 of the principal balance and $4,700 accrued interest during the year ended June 30, 2022. Accordingly, $63,269 of the put premium was released to additional paid in capital in respect to the 1800 Diagonal financing agreements during the year ended June 30, 2022 following conversion of the principal balance.

 

The total principal amount outstanding under the above 1800 Diagonal financing agreements were $237,500 and accrued interest of $5,838 as of September 30, 2022 following conversion of $132,500 of the principal balance and $5,300 accrued interest during the three months ended September 30, 2022. Accordingly, $71,346 of the put premium was released to additional paid in capital in respect to the 1800 Diagonal financing agreements during the three months ended September 30, 2022 following conversion of the principal balance.

 

F-14

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022
(Unaudited)

 

ONE44 Capital Securities Purchase Agreements

 

December 7, 2021 Securities Purchase Agreement

 

Effective December 7, 2021, the Company entered into a securities purchase agreement with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “December 7, 2021 ONE44”) from the Company in the aggregate principal amount of $170,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44 any time after the six-month anniversary of the December 7, 2021 ONE44. The December 7, 2021 ONE44 contained an original discount and debt issue cost for a total of $25,500. The Company used the net proceeds from the December 7, 2021 ONE44 for general working capital purposes. The maturity date of the December 7, 2021 ONE44 is December 7, 2022. The December 7, 2021 ONE44 bore interest at a rate of 10% per annum, which interest may be paid by the Company to ONE44 in shares of the Company’s common stock; but shall not be payable until the December 7, 2021 ONE44 Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

March 29, 2022 Securities Purchase Agreement

 

Effective March 29, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 purchased a convertible promissory note (the “March 29, 2022 ONE44”) from the Company in the aggregate principal amount of $120,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44 any time after the six-month anniversary of the March 29, 2022 ONE44. The December 7, 2021 ONE44 contains an original discount and debt issue cost for a total of $18,000. The Company intends to use the net proceeds from the March 29, 2022 ONE44 for general working capital purposes. The maturity date of the March 29, 2022 ONE44 is March 29, 2023. The March 29, 2022 ONE44 bears interest at a rate of 10% per annum, which interest may be paid by the Company to ONE44 in shares of the Company’s common stock; but shall not be payable until the March 29, 2022 ONE44 Note becomes payable, whether at the maturity date or upon acceleration or by prepayment.

 

August 15, 2022 Securities Purchase Agreement

 

On August 15, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 Capital purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $110,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44 Capital any time after the six-month anniversary of the August 15, 2022 ONE44 Note. The transaction contemplated by the ONE44 Purchase Agreement closed on August 16, 2022. The August 15, 2022 One44 Note contains an original issue discount amount of $10,000. Pursuant to the terms of the August 15, 2022 ONE44 Purchase Agreement, the Company will pay ONE44 Capital’s legal fees of $5,500. The Company intends to use the net proceeds from the August 15, 2022 ONE44 Note for general working capital purposes. The maturity date of the August 15, 2022 One44 Note is August 15, 2023. The August 15, 2022 ONE44 Note shall bear interest at a rate of 10% per annum, which interest may be paid by the Company to ONE44 Capital in shares of common stock, but shall not be payable until the Maturity Date or upon acceleration or by prepayment

 

The following terms shall apply to all the above ONE44 notes:

 

During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 120% to 135% as defined in the note agreement. After this initial 180-day period, the Company does not have a right to prepay such notes.

 

The conversion price for the above ONE44 notes shall be equal to 65% (representing a 35% discount) of the market price which means the lowest closing bid prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, ONE44 shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by ONE44 and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. All of the above ONE44 notes are treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $215,385 put premium of which $